Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Portfolio Pulse from Vandana Singh
Amgen Inc (NASDAQ:AMGN) announced positive Phase 3 trial results for Uplizna in treating Immunoglobulin G4-related disease. The trial met all primary and secondary endpoints, showing significant efficacy and safety. Amgen plans to seek expanded US approval for Uplizna, which was acquired through a $27.8 billion deal with Horizon Therapeutics.
June 05, 2024 | 7:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's Phase 3 trial for Uplizna showed significant efficacy and safety in treating IgG4-related disease. The company plans to seek expanded US approval, which could boost its market position and revenue.
The positive trial results and plans for expanded approval are likely to enhance Amgen's market position and revenue potential. The news is highly relevant and important for investors, indicating a likely positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100